<p>Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer</p>

Abstract

Introduction: The prognostic significance of the systemic immune-inflammation index (SII) in breast cancer is unknown. Here, we aimed to explore the connection between pretreatment SII and the survival of patients with triple-negative breast cancer (TNBC). Methods: We enrolled 160 TNBC patients treated in our hospital between May 2000 and June 2012. We employed the Kaplan-Meier curve and log-rank test to assess overall survival (OS), disease-free survival (DFS), and distant metastasis-free survival (DMFS). We identified the prognostic significance of SII using the Cox regression model. Results: The Kaplan-Meier curve revealed the median OS as 44.2 and 82.4 months in high and low SII TNBC patients, respectively ( P <0.001). According to univariate and multivariate analyses, increased SII correlated with poor OS (HR =2.91, 95% CI: 2.00–4.23, P <0.001; HR =2.60, 95% CI: 1.74–3.88, P <0.001). The DFS and DMFS of patients with high SII were 18.8 and 23.8 months, respectively, while those of patients with low SII were 29 and 45.2 months, respectively, ( P <0.001). Further univariate analyses showed a significant correlation between SII and DFS and DMFS ( P <0.01), while results from multivariate analyses suggested that SII is an independent prognostic factor for DFS ( P =0.045), but not for DMFS ( P =0.078). The area under the receiver operating characteristics curves for SII to differentiate between long and short OS, DFS, and DMFS were 0.69, 0.60, and 0.64, respectively. Conclusion: Our findings may point to SII having an independent prognostic significance in TNBC patients. Prospective in-depth studies, using a larger sample size, are required to further investigate the precise role of SII in TNBC before clinical use.

Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

“…No additional records were identified through manual searching. Finally, 9 published articles involving 2724 patients were included in this meta-analysis [11][12][13][14][15][16][20][21][22]. Among these 9 studies, two [11,14] contained the training and validation cohorts from different hospitals, and thus, 11 datasets were totally used for statistical analysis (Table 1).…”

“…Among these 9 studies, two [11,14] contained the training and validation cohorts from different hospitals, and thus, 11 datasets were totally used for statistical analysis (Table 1). Two studies [14,20] evaluated the relationship between SII index and prognosis in cervical cancer patients, five [12,13,16,21,22] focused on breast cancer, and two [11,15] investigated ovarian cancer. In the study of De Giorgi et al, triple-negative, HER2+, and HER2-ER+ subtypes of breast cancer were also independently analyzed, in addition to the overall results [16]; while all the other studies [12,13,21,22] on breast cancer only focused on specific breast cancer subtypes.…”

“…For example, a retrospective study in ovarian cancer patients showed that SII was an independent prognostic indicator for OS and progression-free survival (PFS) not only in the training cohort [OS: hazard ratio (HR) = 6.36, 95% confidence interval (CI) = 2.64-15.33; P < 0.001; PFS: HR = 7.61, 95%CI = 3.34-17.35; P < 0.001], but also in the discovery cohort (OS: HR = 1.96, 95%CI = 1.09-3.63; P = 0.024; PFS: HR = 2.71, 95%CI = 1.48-4.93; P = 0.001) [11]. Multivariate analysis proved that increased SII correlated with poor OS (Liu et al: HR = 2.60, 95% CI = 1.74-3.88; P < 0.001 [12]; Wang et al: HR = 2.96, 95% CI = 2.18-3.98; P < 0.00 1 [13]) and DFS (Liu et al: HR = 1.46, 95% CI = 1.01-2.12; P = 0.045 [12]; Wang et al: HR = 2.85, 95% CI = 1.62-3.81; P = 0.005 [13]) in patients with triple-negative breast cancer. Using primary (HR = 2.53, 95% CI = 1.32-4.83; P = 0.005) and validation (HR = 3.99, 95% CI = 1.388-11.47; P = 0.010) cohorts, the study of Huang et al supported that SII was an independent risk factor for prediction of OS in cervical cancer patients [14].…”

“…Gynecological and breast cancers are the two leading causes of death among women [1]. According to the epidemiological investigation in the USA in 2019, breast cancer was responsible for 41,760 deaths, followed by ovarian cancer (13,980), uterine corpus endometrial cancer (12,160), cervical cancer (4250), and vulvar cancer (1280) [2]. Recurrence and metastasis are the main contributors for the treatment failure and poor outcomes of these gynecological and breast cancer patients.…”

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer

“…Recently, a new inflammatory index, the systemic immune-inflammation index (SII), defined as neutrophil × platelet/lymphocyte, integrates three inflammatory cells and has been shown to be promising [12]. The prognostic value of SII has been confirmed in various cancers, including NSCLC [13], small cell lung cancer [14], esophageal squamous cell carcinoma (SqCC) [15], breast cancer [16] and hepatocellular cancer [17]. However, to the best of our knowledge, the association of SII with tumor progression and the implication of SII in postoperative adjuvant chemotherapy in operable NSCLC patients remain largely unknown.…”